Duggan has not replaced prior mgt ...Darren Uecker is still Ceo . Suggest you read up on the history of their working relationship ...Computer motion to Intuitive Surgical to Pharmacyclics to PLSE . This is one team I would not bet against . This will be a volatile stock IMHO so there will be other entry pts...
If you are up for it ....take a hard look ( as in critical appraisal ) of MYOK . Following recent FDA meeting , PVOT approved as endpt ...FDA did not require reduction in MACE ( heart attacks , strokes ) . Details on pivotal P3 design in Q1 2018 ...will be a fairly short trial with only 200-250 enrolled . 15% improvement in endpt is considered clinically meaningful . Presentation this weekend at AHA
News 
Market Data 
Discover 
